Molecular Changes in Fatty Acid Oxidation in the Failing Heart

  • Jagdip S. Jaswal
  • Wendy Keung
  • Wei Wang
  • John R. Ussher
  • Gary D. Lopaschuk
Chapter

Abstract

Heart failure is emerging as a leading cause of morbidity and mortality in developed countries and is accompanied by alterations in myocardial fatty acid metabolism. In contrast to the normal heart, where fatty acid and glucose metabolism are reciprocally regulated, this dynamic relationship is perturbed in the failing heart. These metabolic alterations negatively impact both cardiac efficiency and function. Depending on the severity/stage of heart failure, the contribution of overall myocardial oxidative metabolism (fatty acid β-oxidation and glucose oxidation) to adenosine triphosphate (ATP) production can be depressed. Nonetheless, the balance between fatty acid β-oxidation and glucose oxidation is amenable to pharmacological intervention at multiple levels of each metabolic pathway. The alterations in fatty acid β-oxidation and the associated metabolic phenotype of accompany heart failure are described here. Furthermore, as myocardial fatty acid β-oxidation has emerged as a novel therapeutic target to limit the decrements in ventricular function, the rationale for the use of pharmacological agents that optimize fatty acid β-oxidation to improve cardiac function in the setting of heart failure will be described.

Keywords

Heart failure Cardiac efficiency Fatty acid oxidation Glucose oxidation Mitochondria 

Notes

Acknowledgments

This work was supported by a grant from the Canadian Institutes of Health Research to G.D.L. G.D.L. is an Alberta Heritage Foundation for Medical Research (AHFMR) Scientist. W.K. is supported by fellowship awards from the Heart and Stroke Foundation of Canada and AHFMR. W.W. is supported by a fellowship award from AHFMR. J.R.U. is supported by fellowship awards from AHFMR and the Canadian Institutes of Health Research.

References

  1. 1.
    Lopaschuk GD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Neubauer S. The failing heart – an engine out of fuel. N Engl J Med. 2007;356:1140–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093–129.PubMedCrossRefGoogle Scholar
  4. 4.
    Bing RJ, Siegel A, Ungar I, et al. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Neely JM, Morgan HE. Relationship between carbohydrate metabolism and energy balance of heart muscle. Ann Rev Physiol. 1974;36:413–59.CrossRefGoogle Scholar
  6. 6.
    Opie LH. Metabolism of the heart in health and disease. I. Am Heart J. 1968;76:685–98.PubMedCrossRefGoogle Scholar
  7. 7.
    Opie LH. Metabolism of the heart in health and disease. II. Am Heart J. 1969;77:100–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Messer JV, Neill WA. The oxygen supply of the human heart. Am J Cardiol. 1962;9:384–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Messer JV, Wagman RJ, Levine HJ, et al. Patterns of human myocardial oxygen extraction during rest and exercise. J Clin Invest. 1962;41:725–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–98.PubMedCrossRefGoogle Scholar
  11. 11.
    Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50:2128–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–90.PubMedCrossRefGoogle Scholar
  13. 13.
    McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365:1877–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol. 2009;54:1637–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem. 1991;266:8162–70.PubMedGoogle Scholar
  17. 17.
    Saddik M, Lopaschuk GD. The fate of arachidonic acid and linoleic acid in isolated working rat hearts containing normal or elevated levels of coenzyme A. Biochim Biophys Acta. 1991;1086:217–24.PubMedGoogle Scholar
  18. 18.
    Saddik M, Lopaschuk GD. Myocardial triglyceride turnover during reperfusion of solated rat hearts subjected to a transient period of global ischemia. J Biol Chem. 1992;267:3825–31.PubMedGoogle Scholar
  19. 19.
    Eaton RP. Synthesis of plasma triglycerides in endogenous hypertriglyceridemia. J Lipid Res. 1971;12:491–7.PubMedGoogle Scholar
  20. 20.
    van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45:279–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Bonen A, Campbell SE, Benton CR, et al. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc. 2004;63:245–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Koonen DP, Glatz JF, Bonen A, et al. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta. 2005;1736:163–80.PubMedGoogle Scholar
  23. 23.
    Luiken JJ, Coort SL, Koonen DP, et al. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch. 2004;448:1–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Murthy MS, Pande SV. Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. J Biol Chem. 1984;259:9082–9.PubMedGoogle Scholar
  25. 25.
    Murthy MS, Pande SV. Some differences in the properties of carnitine palmitoyltransferase activities of the mitochondrial outer and inner membranes. Biochem J. 1987;248:727–33.PubMedGoogle Scholar
  26. 26.
    Murthy MS, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci USA. 1987;84:378–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7:115–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Wolff AA, Rotmensch HH, Stanley WC, et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians’ perspective. Heart Fail Rev. 2002;7:187–203.PubMedCrossRefGoogle Scholar
  29. 29.
    McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;244:1–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Schulz H. Oxidation of fatty acids in eukaryotes. 5th ed. Amsterdam: Elsevier; 2007.Google Scholar
  31. 31.
    Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol. 2002;34:1099–109.PubMedCrossRefGoogle Scholar
  32. 32.
    Kudo N, Barr AJ, Barr RL, et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Frayn KN, Arner P, Yki-Jarvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem. 2006;42:89–103.PubMedCrossRefGoogle Scholar
  34. 34.
    Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 1998;14:263–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Folmes CD, Lopaschuk GD. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovasc Res. 2007;73:278–87.PubMedCrossRefGoogle Scholar
  37. 37.
    Ussher JR, Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res. 2008;79:259–68.PubMedCrossRefGoogle Scholar
  38. 38.
    Ussher JR, Lopaschuk GD. Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Res Cardiol. 2009;104:203–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Paulson DJ, Ward KM, Shug AL. Malonyl CoA inhibition of carnitine palmityltransferase in rat heart mitochondria. FEBS Lett. 1984;176:381–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Saggerson ED. Carnitine acyltransferase activities in rat liver and heart measured with palmitoyl-CoA and octanoyl-CoA. Latency, effects of K+, bivalent metal ions and malonyl-CoA. Biochem J. 1982;202:397–405.PubMedGoogle Scholar
  41. 41.
    McGarry JD, Leatherman GF, Foster DW. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem. 1978;253:4128–36.PubMedGoogle Scholar
  42. 42.
    Reszko AE, Kasumov T, David F, et al. Regulation of malonyl-CoA concentration and turnover in the normal heart. J Biol Chem. 2004;279:34298–342301.PubMedCrossRefGoogle Scholar
  43. 43.
    Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans. 2002;30:1059–64.PubMedCrossRefGoogle Scholar
  44. 44.
    Comte B, Vincent G, Bouchard B, et al. A 13C mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts. J Biol Chem. 1997;272:26125–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Poirier M, Vincent G, Reszko AE, et al. Probing the link between citrate and malonyl-CoA in perfused rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1379–86.PubMedGoogle Scholar
  46. 46.
    Carling D, Aguan K, Woods A, et al. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. J Biol Chem. 1994;269:11442–8.PubMedGoogle Scholar
  47. 47.
    Dyck JR, Gao G, Widmer J, et al. Regulation of 5′-AMP-activated protein kinase activity by the ­noncatalytic beta and gamma subunits. J Biol Chem. 1996;271:17798–8803.PubMedCrossRefGoogle Scholar
  48. 48.
    Gao J, Waber L, Bennett MJ, et al. Cloning and mutational analysis of human malonyl-coenzyme A decarboxylase. J Lipid Res. 1999;40:178–82.PubMedGoogle Scholar
  49. 49.
    Hardie DG. Regulation of fatty acid synthesis via phosphorylation of acetyl-CoA carboxylase. Prog Lipid Res. 1989;28:117–46.PubMedCrossRefGoogle Scholar
  50. 50.
    Hardie DG. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim Biophys Acta. 1992;1123:231–8.PubMedGoogle Scholar
  51. 51.
    Hardie DG. An emerging role for protein kinases: the response to nutritional and environmental stress. Cell Signal. 1994;6:813–21.PubMedCrossRefGoogle Scholar
  52. 52.
    Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem. 1996;271:27879–87.PubMedCrossRefGoogle Scholar
  53. 53.
    Stapleton D, Woollatt E, Mitchelhill KI, et al. AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett. 1997;409:452–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Weekes J, Hawley SA, Corton J, et al. Activation of rat liver AMP-activated protein kinase by kinase kinase in a purified, reconstituted system. Effects of AMP and AMP analogues. Eur J Biochem. 1994;219:751–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Wasserman DH, Ayala JE. Interaction of physiological mechanisms in control of muscle glucose uptake. Clin Exp Pharmacol Physiol. 2005;32:319–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Becker C, Sevilla L, Tomas E, et al. The endosomal compartment is an insulin-sensitive recruitment site for GLUT4 and GLUT1 glucose transporters in cardiac myocytes. Endocrinol. 2001;142:5267–76.CrossRefGoogle Scholar
  57. 57.
    Fischer Y, Thomas J, Sevilla L, et al. Insulin-induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. Evidence of the existence of different intracellular GLUT4 vesicle populations. J Biol Chem. 1997;272:7085–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Schwenk RW, Luiken JJ, Bonen A, et al. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008;79:249–58.PubMedCrossRefGoogle Scholar
  59. 59.
    Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89:3–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Zierler K. Whole body glucose metabolism. Am J Physiol. 1999;276:E409–26.PubMedGoogle Scholar
  61. 61.
    Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol. 1993;264:C761–82.PubMedGoogle Scholar
  62. 62.
    Panchal AR, Comte B, Huang H, et al. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol. 2001;281:H1613–20.PubMedGoogle Scholar
  63. 63.
    Panchal AR, Comte B, Huang H, et al. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol. 2000;279:H2390–8.PubMedGoogle Scholar
  64. 64.
    Pound KM, Sorokina N, Ballal K, et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009;104:805–12.PubMedCrossRefGoogle Scholar
  65. 65.
    Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 2003;284:E855–62.PubMedGoogle Scholar
  66. 66.
    Kolobova E, Tuganova A, Boulatnikov I, et al. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J. 2001;358:69–77.PubMedCrossRefGoogle Scholar
  67. 67.
    Korotchkina LG, Patel MS. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J Biol Chem. 2001;276:37223–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Holness MJ, Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans. 2003;31:1143–51.PubMedCrossRefGoogle Scholar
  69. 69.
    Spriet LL, Heigenhauser GJ. Regulation of pyruvate dehydrogenase (PDH) activity in human skeletal muscle during exercise. Exerc Sport Sci Rev. 2002;30:91–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol. 1991;23:1077–86.PubMedCrossRefGoogle Scholar
  71. 71.
    Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol. 2004;287:R502–16.PubMedCrossRefGoogle Scholar
  72. 72.
    Lysiak W, Toth PP, Suelter CH, et al. Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem. 1986;261:13698–703.PubMedGoogle Scholar
  73. 73.
    Bing RJ, Hammond MM, Handelsman JC, et al. The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am Heart J. 1949;38:1–24.PubMedCrossRefGoogle Scholar
  74. 74.
    Suga H. Cardiac energetics: from E(max) to pressure-volume area. Clin Exp Pharmacol Physiol. 2003;30:580–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Suga H. Ventricular energetics. Physiol Rev. 1990;70:247–77.PubMedGoogle Scholar
  76. 76.
    Jaswal JS, Ussher JR, Lopaschuk GD. Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. Future Lipidol. 2009;4:379–89.Google Scholar
  77. 77.
    Boudina S, Sena S, O’Neill BT, et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005;112:2686–95.PubMedCrossRefGoogle Scholar
  78. 78.
    Hafstad AD, Khalid AM, How OJ, et al. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2007;292:E1288–94.PubMedCrossRefGoogle Scholar
  79. 79.
    How OJ, Aasum E, Severson DL, et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes. 2006;55:466–73.PubMedCrossRefGoogle Scholar
  80. 80.
    Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007;56:2457–66.PubMedCrossRefGoogle Scholar
  81. 81.
    Mazumder PK, O’Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes. 2004;53:2366–74.PubMedCrossRefGoogle Scholar
  82. 82.
    Huang Y, Hunyor SN, Jiang L, et al. Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses. Am J Physiol Heart Circ Physiol. 2004;286:H2141–50.PubMedCrossRefGoogle Scholar
  83. 83.
    Kameyama T, Chen Z, Bell SP, et al. Mechanoenergetic alterations during the transition from cardiac hypertrophy to failure in Dahl salt-sensitive rats. Circulation. 1998;98:2919–29.PubMedGoogle Scholar
  84. 84.
    Bengel FM, Permanetter B, Ungerer M, et al. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 ­acetate – comparison between the normal and failing human heart. Eur J Nucl Med. 2000;27:319–26.PubMedCrossRefGoogle Scholar
  85. 85.
    Morii I, Kihara Y, Inoko M, et al. Myocardial contractile efficiency and oxygen cost of contractility are preserved during transition from compensated hypertrophy to failure in rats with salt-sensitive hypertension. Hypertension. 1998;31:949–60.PubMedGoogle Scholar
  86. 86.
    Hinkle PC. P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta. 2005;1706:1–11.PubMedCrossRefGoogle Scholar
  87. 87.
    Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim Biophys Acta. 2003;1604:77–94.PubMedCrossRefGoogle Scholar
  88. 88.
    Murray AJ, Panagia M, Hauton D, et al. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes. 2005;54:3496–502.PubMedCrossRefGoogle Scholar
  89. 89.
    Boehm EA, Jones BE, Radda GK, et al. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol. 2001;280:H977–83.PubMedGoogle Scholar
  90. 90.
    Hidaka S, Kakuma T, Yoshimatsu H, et al. Streptozotocin treatment upregulates uncoupling protein 3 expression in the rat heart. Diabetes. 1999;48:430–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Bugger H, Boudina S, Hu XX, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes. 2008;57:2924–32.PubMedCrossRefGoogle Scholar
  92. 92.
    Murray AJ, Anderson RE, Watson GC, et al. Uncoupling proteins in human heart. Lancet. 2004;364:1786–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Murray AJ, Cole MA, Lygate CA, et al. Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. J Mol Cell Cardiol. 2008;44:694–700.PubMedCrossRefGoogle Scholar
  94. 94.
    Seifert EL, Bezaire V, Estey C, et al. Essential role for uncoupling protein-3 in mitochondrial adaptation to fasting but not in fatty acid oxidation or fatty acid anion export. J Biol Chem. 2008;283:25124–31.PubMedCrossRefGoogle Scholar
  95. 95.
    Hunt MC, Alexson SE. The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog Lipid Res. 2002;41:99–130.PubMedCrossRefGoogle Scholar
  96. 96.
    Burgmaier M, Sen S, Philip F, Wilson CR, et al. Metabolic adaptation follows contractile dysfunction in the heart of obese zucker rats fed a high-fat “Western” diet. Obesity (Silver Spring). 2010;18:1895–901.CrossRefGoogle Scholar
  97. 97.
    Stavinoha MA, RaySpellicy JW, Essop MF, et al. Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-alpha-regulated gene in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab. 2004;287:E888–95.PubMedCrossRefGoogle Scholar
  98. 98.
    King KL, Young ME, Kerner J, et al. Diabetes or peroxisome proliferator-activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart. J Lipid Res. 2007;48:1511–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Himms-Hagen J, Harper ME. Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med (Maywood). 2001;226:78–84.Google Scholar
  100. 100.
    Myrmel T, Forsdahl K, Larsen TS. Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol. 1992;24:855–68.PubMedCrossRefGoogle Scholar
  101. 101.
    Klocke R, Tian W, Kuhlmann MT, et al. Surgical animal models of heart failure related to coronary heart disease. Cardiovasc Res. 2007;74:29–38.PubMedCrossRefGoogle Scholar
  102. 102.
    Monnet E, Chachques JC. Animal models of heart failure: what is new? Ann Thorac Surg. 2005;79:1445–53.PubMedCrossRefGoogle Scholar
  103. 103.
    Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267–74.PubMedCrossRefGoogle Scholar
  104. 104.
    Conway MA, Allis J, Ouwerkerk R, et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet. 1991;338:973–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Nascimben L, Friedrich J, Liao R, et al. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation. 1995;91:1824–33.PubMedGoogle Scholar
  106. 106.
    Tian R, Nascimben L, Kaddurah-Daouk R, et al. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol. 1996;28:755–65.PubMedCrossRefGoogle Scholar
  107. 107.
    Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81:412–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135–45.PubMedCrossRefGoogle Scholar
  109. 109.
    Neubauer S, Krahe T, Schindler R, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810–8.PubMedGoogle Scholar
  110. 110.
    Degens H, de Brouwer KF, Gilde AJ, et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol. 2006;101:17–26.PubMedCrossRefGoogle Scholar
  111. 111.
    de Brouwer KF, Degens H, Aartsen WM, et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J Mol Cell Cardiol. 2006;40:838–45.PubMedCrossRefGoogle Scholar
  112. 112.
    O’Donnell JM, Fields AD, Sorokina N, et al. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol. 2008;44:315–22.PubMedCrossRefGoogle Scholar
  113. 113.
    Chandler MP, Kerner J, Huang H, et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2004;287:H1538–43.PubMedCrossRefGoogle Scholar
  114. 114.
    Grover-McKay M, Schwaiger M, Krivokapich J, et al. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:317–24.PubMedCrossRefGoogle Scholar
  115. 115.
    Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1998;81:45–50.PubMedCrossRefGoogle Scholar
  116. 116.
    Paolisso G, Gambardella A, Galzerano D, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 1994;43:174–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Taylor M, Wallhaus TR, Degrado TR, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with (18F)fluoro-6-thia-heptadecanoic acid and (18F)FDG in Patients with Congestive Heart Failure. J Nucl Med. 2001;42:55–62.PubMedGoogle Scholar
  118. 118.
    Bugger H, Schwarzer M, Chen D. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res. 2010;85(2):376–84.PubMedCrossRefGoogle Scholar
  119. 119.
    Doenst T, Pytel G, Schrepper A, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res. 2010;86:461–70.PubMedCrossRefGoogle Scholar
  120. 120.
    Lei B, Lionetti V, Young ME, et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol. 2004;36:567–76.PubMedCrossRefGoogle Scholar
  121. 121.
    Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106:606–12.PubMedCrossRefGoogle Scholar
  122. 122.
    Qanud K, Mamdani M, Pepe M, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol. 2008;295:H2098–105.PubMedCrossRefGoogle Scholar
  123. 123.
    Neglia D, De Caterina A, Marraccini P, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293:H3270–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114:2130–7.PubMedCrossRefGoogle Scholar
  125. 125.
    Taegtmeyer H. Metabolism – the lost child of cardiology. J Am Coll Cardiol. 2000;36:1386–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645–51.PubMedCrossRefGoogle Scholar
  127. 127.
    Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004;1:42–7.PubMedGoogle Scholar
  128. 128.
    Pepper GS, Lee RW. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med. 1999;159:225–34.PubMedCrossRefGoogle Scholar
  129. 129.
    Morris MJ, Cox HS, Lambert GW, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997;29:137–43.PubMedGoogle Scholar
  130. 130.
    Bohm M, La Rosee K, Schwinger RH, et al. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146–53.PubMedCrossRefGoogle Scholar
  131. 131.
    Engelhardt S, Bohm M, Erdmann E, et al. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol. 1996;27:146–54.PubMedCrossRefGoogle Scholar
  132. 132.
    Neely JR, Whitmer M, Mochizuki S. Effects of mechanical activity and hormones on myocardial glucose and fatty acid utilization. Circ Res. 1976;38(5 Suppl 1):I22–30.PubMedGoogle Scholar
  133. 133.
    Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia. 2000;43:533–49.PubMedCrossRefGoogle Scholar
  134. 134.
    Marangou AG, Alford FP, Ward G, et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism. 1988;37:885–91.PubMedCrossRefGoogle Scholar
  135. 135.
    Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142:720–4.PubMedCrossRefGoogle Scholar
  136. 136.
    Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104:12587–94.PubMedCrossRefGoogle Scholar
  137. 137.
    Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Doehner W, von Haehling S, Anker SD. Insulin resistance in chronic heart failure. J Am Coll Cardiol. 2008;52:239. author reply 239–240.PubMedCrossRefGoogle Scholar
  139. 139.
    Dutka DP, Pitt M, Pagano D, et al. Myocardial ­glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006;48:2225–31.PubMedCrossRefGoogle Scholar
  140. 140.
    Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial ­glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955–61.PubMedCrossRefGoogle Scholar
  141. 141.
    Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H2401–8.PubMedCrossRefGoogle Scholar
  142. 142.
    Aasum E, Belke DD, Severson DL, et al. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002;283:H949–57.PubMedGoogle Scholar
  143. 143.
    Aasum E, Hafstad AD, Severson DL, et al. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003;52:434–41.PubMedCrossRefGoogle Scholar
  144. 144.
    Aasum E, Khalid AM, Gudbrandsen OA, et al. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol. 2008;44:201–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Buchanan J, Mazumder PK, Hu P, et al. Reduced ­cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146:5341–9.PubMedCrossRefGoogle Scholar
  146. 146.
    Hafstad AD, Solevag GH, Severson DL, et al. Perfused hearts from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin. Am J Physiol Heart Circ Physiol. 2006;290:H1763–9.PubMedCrossRefGoogle Scholar
  147. 147.
    How OJ, Aasum E, Kunnathu S, et al. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol. 2005;288:H2979–85.PubMedCrossRefGoogle Scholar
  148. 148.
    Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Ussher JR, Koves TR, Jaswal JS, et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes. 2009;58:1766–75.PubMedCrossRefGoogle Scholar
  150. 150.
    Brisse B, Tetsch P, Jacobs W, et al. Beta-adrenoceptor blockade in stress due to oral surgery. Br J Clin Pharmacol. 1982;13 Suppl 2:421S–7.PubMedGoogle Scholar
  151. 151.
    Newman RJ. Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man. Br Med J. 1977;2:601–3.PubMedCrossRefGoogle Scholar
  152. 152.
    Fellander G, Eleborg L, Bolinder J, et al. Microdialysis of adipose tissue during surgery: effect of local alpha- and beta-adrenoceptor blockade on blood flow and lipolysis. J Clin Endocrinol Metab. 1996;81:2919–24.PubMedCrossRefGoogle Scholar
  153. 153.
    Igarashi N, Nozawa T, Fujii N, et al. Influence of beta-adrenoceptor blockade on the myocardial accumulation of fatty acid tracer and its intracellular metabolism in the heart after ischemia-reperfusion injury. Circ J. 2006;70:1509–14.PubMedCrossRefGoogle Scholar
  154. 154.
    Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441–6.PubMedGoogle Scholar
  155. 155.
    Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82:473–83.PubMedCrossRefGoogle Scholar
  156. 156.
    Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310–20.PubMedCrossRefGoogle Scholar
  157. 157.
    Panchal AR, Stanley WC, Kerner J, et al. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail. 1998;4:121–6.PubMedCrossRefGoogle Scholar
  158. 158.
    Podbregar M, Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail. 2002;8:369–78.PubMedCrossRefGoogle Scholar
  159. 159.
    Al-Hesayen A, Azevedo ER, Floras JS, et al. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail. 2005;7:618–23.PubMedCrossRefGoogle Scholar
  160. 160.
    Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008;44:968–75.PubMedCrossRefGoogle Scholar
  161. 161.
    Cook WS, Yeldandi AV, Rao MS, et al. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem Biophys Res Commun. 2000;278:250–7.PubMedCrossRefGoogle Scholar
  162. 162.
    Schoonjans K, Staels B, Grimaldi P, et al. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem. 1993;216:615–22.PubMedCrossRefGoogle Scholar
  163. 163.
    Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027–40.PubMedCrossRefGoogle Scholar
  164. 164.
    Prasad MR, Clement R, Otani H, et al. Improved myocardial performance induced by clofibrate during reperfusion after acute myocardial infarction. Can J Physiol Pharmacol. 1988;66:1518–23.PubMedCrossRefGoogle Scholar
  165. 165.
    Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004;10:1245–50.PubMedCrossRefGoogle Scholar
  166. 166.
    Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518–24.PubMedCrossRefGoogle Scholar
  167. 167.
    Hondares E, Pineda-Torra I, Iglesias R, et al. PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. Biochem Biophys Res Commun. 2007;354:1021–7.PubMedCrossRefGoogle Scholar
  168. 168.
    Pellieux C, Montessuit C, Papageorgiou I, et al. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc Res. 2009;82:341–50.PubMedCrossRefGoogle Scholar
  169. 169.
    Planavila A, Laguna JC, Vazquez-Carrera M. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem. 2005;280:17464–71.PubMedCrossRefGoogle Scholar
  170. 170.
    Burkart EM, Sambandam N, Han X, et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007;117:3930–9.PubMedGoogle Scholar
  171. 171.
    Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes. 2002;51:1110–7.PubMedCrossRefGoogle Scholar
  172. 172.
    Zhu P, Lu L, Xu Y, et al. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 2000;101:1165–71.PubMedGoogle Scholar
  173. 173.
    Yue TL, Bao W, Gu JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005;54:554–62.PubMedCrossRefGoogle Scholar
  174. 174.
    Okere IC, Chandler MP, McElfresh TA, et al. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet. Clin Exp Pharmacol Physiol. 2007;34:113–9.PubMedCrossRefGoogle Scholar
  175. 175.
    Lindenfeld J, Masoudi FA. Fluid retention with thiazolidinediones: does the mechanism influence the outcome? J Am Coll Cardiol. 2007;49:1705–7.PubMedCrossRefGoogle Scholar
  176. 176.
    Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRefGoogle Scholar
  177. 177.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRefGoogle Scholar
  178. 178.
    Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010; in pressGoogle Scholar
  179. 179.
    Reaven GM, Chang H, Hoffman BB. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes. 1988;37:28–32.PubMedCrossRefGoogle Scholar
  180. 180.
    Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem. 1989;88:175–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Lopaschuk GD, Spafford MA, Davies NJ, et al. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res. 1990;66:546–53.PubMedGoogle Scholar
  182. 182.
    Lopaschuk GD, Wall SR, Olley PM, et al. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988;63:1036–43.PubMedGoogle Scholar
  183. 183.
    Schmitz FJ, Rosen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Horm Metab Res. 1995;27:515–22.PubMedCrossRefGoogle Scholar
  184. 184.
    Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta. 1989;1006:97–103.PubMedGoogle Scholar
  185. 185.
    Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation. 1997;96:3681–6.PubMedGoogle Scholar
  186. 186.
    Rupp H, Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br J Pharmacol. 2000;131:1748–56.PubMedCrossRefGoogle Scholar
  187. 187.
    Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond). 2000;99:27–35.CrossRefGoogle Scholar
  188. 188.
    Holubarsch CJ, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond). 2007;113:205–12.CrossRefGoogle Scholar
  189. 189.
    Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280–8.PubMedCrossRefGoogle Scholar
  190. 190.
    Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–8.PubMedGoogle Scholar
  192. 192.
    Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93:e33–7.PubMedCrossRefGoogle Scholar
  193. 193.
    MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2003;93:e26–32.PubMedCrossRefGoogle Scholar
  194. 194.
    Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942–8.PubMedCrossRefGoogle Scholar
  195. 195.
    Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart ­failure. J Am Coll Cardiol. 2006;48:992–8.PubMedCrossRefGoogle Scholar
  196. 196.
    Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250–8.PubMedCrossRefGoogle Scholar
  197. 197.
    Clarke B, Spedding M, Patmore L, et al. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. 1993;109:748–50.PubMedGoogle Scholar
  198. 198.
    Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28:341–50.PubMedCrossRefGoogle Scholar
  199. 199.
    McCormack JG, Baracos VE, Barr R, et al. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol. 1996;81:905–10.PubMedGoogle Scholar
  200. 200.
    McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93:135–42.PubMedGoogle Scholar
  201. 201.
    Wyatt KM, Skene C, Veitch K, Hue L, et al. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol. 1995;50:1599–606.PubMedCrossRefGoogle Scholar
  202. 202.
    Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41:1031–8.PubMedCrossRefGoogle Scholar
  203. 203.
    Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts – role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45:32–43.PubMedCrossRefGoogle Scholar
  204. 204.
    Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6–14.PubMedCrossRefGoogle Scholar
  205. 205.
    Wang P, Fraser H, Lloyd SG, et al. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007;321:213–20.PubMedCrossRefGoogle Scholar
  206. 206.
    Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002;91:278–80.PubMedCrossRefGoogle Scholar
  207. 207.
    Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8:416–22.PubMedCrossRefGoogle Scholar
  208. 208.
    Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295:H2149–55.PubMedCrossRefGoogle Scholar
  209. 209.
    Liu B, Clanachan AS, Schulz R, et al. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 1996;79:940–8.PubMedGoogle Scholar
  210. 210.
    Liu Q, Docherty JC, Rendell JC, et al. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol. 2002;39:718–25.PubMedCrossRefGoogle Scholar
  211. 211.
    Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail. 2010;3:420–30.PubMedCrossRefGoogle Scholar
  212. 212.
    Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J. 1997;134:841–55.PubMedCrossRefGoogle Scholar
  213. 213.
    Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol. 1994;23:1617–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jagdip S. Jaswal
    • 1
  • Wendy Keung
    • 1
  • Wei Wang
    • 1
  • John R. Ussher
    • 1
  • Gary D. Lopaschuk
    • 2
  1. 1.Departments of Pediatrics and Pharmacology, Mazankowski Alberta Heart InstituteUniversity of AlbertaEdmontonCanada
  2. 2.Departments of Pediatrics and PharmacologyUniversity of Alberta, Mazankowski Alberta Heart InstituteEdmontonCanada

Personalised recommendations